Ombitasvir/paritaprevir/ritonavir

DRUG19 trials

Sponsors

AbbVie, Assiut University, National Taiwan University Hospital

Conditions

Antiviral Drug Adverse ReactionChronic Hepatitis CChronic Hepatitis C InfectionChronic Hepatitis C VirusChronic Hepatitis C Virus (HCV) InfectionChronic Hepatitis C, Genotype 1 or 4Compensated CirrhosisDecompensated Cirrhosis

Phase 2

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients

CompletedNCT01782495

AbbVieChronic Hepatitis C Infection

Start: 2013-02-25End: 2017-07-13Updated: 2017-11-07

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

CompletedNCT02486406

AbbVieChronic Hepatitis C Infection

Start: 2015-10-28End: 2020-11-19Updated: 2021-10-05

Phase 3

Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

CompletedNCT02207088

AbbVieChronic Hepatitis C, Compensated Cirrhosis, End-stage Renal Disease +2

Start: 2014-09-23End: 2016-12-06Updated: 2017-11-09

A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection

CompletedNCT02216422

AbbVieChronic Hepatitis C Virus (HCV) Infection

Start: 2014-09-30End: 2015-12-31Updated: 2016-06-29

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

CompletedNCT02219503

AbbVieChronic Hepatitis C Infection, Compensated Cirrhosis

Start: 2014-09-30End: 2015-09-30Updated: 2021-07-12

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis

CompletedNCT02219477

AbbVieChronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus

Start: 2014-11-24End: 2017-03-03Updated: 2017-07-11

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)

CompletedNCT02265237

AbbVieHepatitis C Virus

Start: 2014-10-28End: 2017-04-07Updated: 2017-08-31

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

CompletedNCT02476617

AbbVieChronic Hepatitis C, Hepatitis C Genotype 1a, Hepatitis C (HCV)

Start: 2015-06-30End: 2016-12-31Updated: 2017-10-03

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

CompletedNCT02487199

AbbVieHepatitis C Virus (HCV)

Start: 2015-09-30End: 2016-12-05Updated: 2017-12-04

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

TerminatedNCT02504099

AbbVieChronic Hepatitis C Infection

Start: 2015-07-31End: 2016-12-31Updated: 2017-12-12

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

CompletedNCT02582632

AbbVieHepatitis C Infection, Hepatitis C Virus

Start: 2015-11-24End: 2016-12-01Updated: 2021-07-30

Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)

WithdrawnNCT02806362

AbbVieChronic Hepatitis C Virus

Start: 2016-09-30End: 2018-08-31Updated: 2016-12-05

Phase 4

Effect Of DAAs For Treatment Of HCV On Normal Kidney

Assiut UniversityAntiviral Drug Adverse Reaction

Start: 2017-10-01End: 2018-10-31Target: 100Updated: 2017-09-29

Unknown Phase

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

CompletedNCT02581189

AbbVieChronic Hepatitis C

Start: 2015-10-13End: 2017-12-20Updated: 2019-03-27

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

CompletedNCT02581163

AbbVieChronic Hepatitis C, Genotype 1 or 4

Start: 2015-10-07End: 2018-02-12Updated: 2019-05-06

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland

CompletedNCT02582671

AbbVieChronic Hepatitis C

Start: 2015-11-05End: 2017-11-29Updated: 2019-05-06

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

CompletedNCT02803138

AbbVieChronic Hepatitis C

Start: 2016-07-07End: 2018-10-21Updated: 2019-10-11

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

CompletedNCT03549832

Assiut UniversityHCV Coinfection

Start: 2018-01-01End: 2019-01-30Updated: 2019-03-19

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

CompletedNCT04047680

National Taiwan University HospitalHepatitis C, Renal Disease, Viral Hepatitis C

Start: 2015-02-28End: 2019-06-30Updated: 2019-08-08

Related Papers

Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.

2023-03-2532 citations

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3–11 Years with Hepatitis C Genotype 1a

Advances in Therapy2020-05-2512 citations

Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.

2019-11-2933 citations

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.

2018-10-056 citations

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.

2017-04-1436 citations

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.

2016-06-1636 citations

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease

Gastroenterology2016-03-11277 citations

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

New England Journal of Medicine2014-11-11402 citations